Literature DB >> 12023543

Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys.

Stacy L Sell1, Charles P France.   

Abstract

This study tested the hypothesis that stimulants (indirect dopamine agonists) attenuate the discriminative stimulus of naltrexone in monkeys chronically treated with L-alpha-acetylmethadol (LAAM). Four rhesus monkeys (Macaca mulatta) received LAAM (1.0 mg/kg s.c.) twice daily and discriminated a withdrawal-precipitating dose of naltrexone (0.0178 mg/kg s.c.) from saline. Cocaine (0.1-1.78 mg/kg), amphetamine (0.32-1.78 mg/kg), haloperidol (0.01-0.1 mg/kg), sulpiride (1.0-10.0 mg/kg), propranolol (0.32-3.2 mg/kg), clonidine (0.001-0.1 mg/kg), desipramine (0.32-3.2 mg/kg), and imipramine (1.0-10.0 mg/kg) were given s.c. before cumulative doses of naltrexone. Cocaine and amphetamine antagonized the discriminative stimulus effects of naltrexone, each shifting the naltrexone dose-effect curve significantly (e.g., 100-fold) rightward or downward. In contrast, the dopamine antagonist haloperidol shifted the naltrexone dose-effect curve 5-fold leftward. Sulpiride, desipramine, clonidine, and propranolol had comparatively less effect on the naltrexone discriminative stimulus, whereas some doses of imipramine attenuated the naltrexone stimulus in a manner similar to that of cocaine and amphetamine. These results support the notion that multiple neurotransmitter systems are involved in the discriminative stimulus effects of opioid withdrawal. Furthermore, these data are consistent with reports that dopamine levels decrease during opioid withdrawal and provide evidence that enhancing dopamine or other monoamine levels may attenuate subjective effects of opioid withdrawal.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023543     DOI: 10.1124/jpet.301.3.1103

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

2.  Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys.

Authors:  S Stevens Negus; Kenner C Rice
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

Review 3.  Medications development for opioid abuse.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

4.  Some effects of dopamine transporter and receptor ligands on discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesus monkeys.

Authors:  Lance R McMahon; Jun-Xu Li; F Ivy Carroll; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-07-18       Impact factor: 4.530

5.  Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.

Authors:  G L Becker; L R Gerak; W Koek; C P France
Journal:  Psychopharmacology (Berl)       Date:  2008-08-23       Impact factor: 4.530

Review 6.  Medications Development for Treatment of Opioid Use Disorder.

Authors:  E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Cold Spring Harb Perspect Med       Date:  2021-01-04       Impact factor: 6.915

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.